The results showed that compared with normal tissues, ACSL4 expression was higher in colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lymphoma, myeloma, and pancreatic cancer, but decreased in bladder cancer, brain and CNS cancer, breast cancer, leukemia, lung cancer, and pancreatic cancer. This evidence concerns the gene ACSL4 and urinary bladder cancer.